NEW YORK, NY / ACCESSWIRE / March 31, 2017 / The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired securities of DaVita Inc. (“DaVita”) (NYSE: DVA) between August 5, 2015 and October 21,
2016. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the District of Colorado. To get more information, go to: http://www.zlk.com/pslra/davita-inc, or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

The complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) DaVita and its senior executives purposefully steered patients into needless insurance plans to maximize profits; (2) DaVita was using American Kidney Fund to facilitate these inappropriate practices; (3) therefore, DaVita’s revenues and profits were illegally acquired; (4) as a result, DaVita lacked effective internal controls over financial reporting.

On January 6, 2017, the Wall Street Journal published an article revealing that DaVita had received subpoenas from federal prosecutors seeking “the production of information related to charitable premium assistance” in connection with DaVita’s ties to the American Kidney Fund, a charity that helps patients pay for kidney dialysis.

If you suffered a loss in DaVita, you have until April 3, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street – 24th Floor
New York, NY10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 458668

LOS ANGELES, CA / ACCESSWIRE / March 31, 2017 / Lundin Law PC , a shareholder rights firm, announces a class action lawsuit against Stemline Therapeutics, Inc. (“Stemline” or the “Company”) (NASDAQ: STML) concerning possible violations of federal securities laws on behalf of investors who purchased shares of the Company either (1) pursuant and/or traceable to Stemline’s secondary public offering on or about January 20, 2017; and/or (2) publicly traded on the open market between January 19, 2017 and February 1, 2017, both dates inclusive (the “Class Period”). Investors, who purchased or otherwise acquired shares during Class Period should contact the firm by the April 4, 2017 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

The complaint alleges that during the Class Period, Stemline made false and/or misleading statements and/or failed to disclose that: a cancer patient in a Stemline clinical trial tied to SL-401 died from a severe side effect on January 18, 2017; and thus, the Company’s statements about its business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Lundin Law PC was established by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may be considered Attorney Advertising in certain jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC

Brian Lundin, Esq.

Telephone: 888-713-1033

Facsimile: 888-713-1125

brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 458666

NEW YORK, NY / ACCESSWIRE / March 31, 2017 / The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired shares of Psychemedics Corporation (“Psychemedics”) (NASDAQ: PMD) between February 28, 2014 and January 30, 2017. You are hereby notified that Levi & Korsinsky has commenced the class action Daly v. Psychemedics Corporation, et al. (Case No. 1:17-cv-10186) in the USDC for the District of Massachusetts. Click here to view the complaint. To get more information go to:

http://www.zlk.com/pslra/psychemedics-corporation

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

The complaint alleges that, among other allegations, throughout the Class Period Psychemedics issued materially false and/or misleading statements and/or failed to disclose that Psychemedics’ Brazilian distributor, Psychemedics Brazil, was engaged in illegal anti-competitive practices and may be subject to further investigation by Brazil’s Administrative Council for Economic Defense as a result of this conduct.

On January 31, 2017, Psychemedics issued a press release announcing that a Brazilian court had found Psychemedics Brazil in violation of anti-competition laws and is liable for millions in losses.

Take Action: if you suffered a loss in Psychemedics you have until April 3, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street – 24th Floor
New York, NY10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 458667

VANCOUVER, BC / ACCESSWIRE / March 31, 2017 / Headwind Technologies Ltd. (“Headwind”) is pleased to announce that it has launched its first crowdfunding campaign in Canada. Headwind is currently featured on the Vested Technology Corp. (“Vested”) Canadian equity crowdfunding portal (Vested.ca). Headwind is planning to raise a minimum of $20,000 and a maximum of $250,000, utilizing the start-up crowdfunding exemption, as defined by the British Columbia Securities Commission – BC Instrument 45-535 “Start-up Crowdfunding Registration and Prospectus Exemptions”. Under the crowdfunding exemption, individuals will be able to invest a minimum of $100 and a maximum of $1,500 online, through the Vested.ca portal. (Start-up Crowdfunding Guide for Investors)

Headwind is a Vernon, B.C. based company focused on green, low wind turbine technologies, for residential, recreational and commercial uses. The company is raising funds to brand, market and mass produce the turbine by first introducing it to the North American marketplace. Headwind’s technology is low profile, silent and does not kill birds or bats, which gives Headwind a huge competitive advantage over more conventional wind turbines.

Cannot view this video? Visit:
https://www.youtube.com/watch?v=hAoXPn7GGG8

Vested’s proprietary crowdfunding portal allows individual investors (the Crowd) the opportunity to invest in early stage private Canadian corporations that they typically would not have access to. The Vested.ca portal facilitates the entire process online, including registration, payment and share issuance.

Vested.ca is an equity crowdfunding platform that connects start-up businesses with investors across Canada. Companies can raise up to $250,000 twice a year for a total of $500,000 annually, utilizing the crowdfunding exemption. Individuals can invest up to $1,500 and a minimum of $100 in the Issuer and campaigns are open for a 90-day period.

For further information please contact:

Mr. Barron McConnachie, CFO
Headwind Technologies Ltd.
barron12@shaw.ca
www.headwindtechnologies.ca

SOURCE: Headwind Technologies Ltd.

ReleaseID: 458665

NEW YORK, NY / ACCESSWIRE / March 31, 2017 / Achillion’s stock yesterday were not as volatile as Wednesday with the value increasing by the close of business yesterday. Corbus Pharma is also struggling, but the positive results from the second phase of the clinical drug trials are set to shed some optimistic light on the company’s stock going forward.

RDI Initiates
Coverage:

Achillion
Pharmaceuticals, Inc. https://ub.rdinvesting.com/news/?ticker=ACHN

Corbus
Pharmaceuticals Holdings Inc. https://ub.rdinvesting.com/news/?ticker=CRBP

Achiullion Pharmaceuticals stock closed yesterday on a high, with the share price increasing marginally. The company’s stock closed at $4.28, a 0.23% rise from the previous closing. It has been a month since the company released its latest earnings report and the stock value has plummeted 11.3%, with the data indicating underperformance of the stock in terms of trade volume. Achillion’s EPS dipped 0.03% during the fourth quarter financial period. The company’s Q4 revenue was reduced by half, reporting $15 million, compared to $31.6 million registered a year ago.

The company’s expenses increased, with overall spending on drug trials, manufacturing and consulting costs making up the majority of the operating expenses of $15 million. Analysts have remained quiet on the company’s 2017 estimates. The company is still struggling to offset competition, facilitate clinical trials.

Access RDI’s Achillion Pharmaceuticals Research Report
at: https://ub.rdinvesting.com/news/?ticker=ACHN

The company’s stock struggled to remain on the green yesterday, to close at $7.95. By midday, the price had shot up to register highs of $8.45, but this barely lasted until 4pm. The phase 2 study of the clinical drug trial is now complete, after completion of the phase 1 study a fortnight ago. The results were positive, with the probability rate of success on the Cystic Fibrosis research going up by 50% from 30%.

The additional funds boosted the research’s success probability. The company announced that the main focus of the phase 2 study is to ensure the patients’ safety. The company is working to ensure that the patient’s condition does not deteriorate due to therapeutic procedures.

Access RDI’s Corbus Pharmaceuticals Research Report at: https://ub.rdinvesting.com/news/?ticker=CRBP

Our Actionable Research on Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) and Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 458639

TORONTO, ON / ACCESSWIRE / March 31, 2017 / StableView Asset Management (“StableView”) announces that it has acquired control or direction over an additional 400,000 common shares in the capital of Clarocity Corporation (“Clarocity”), debentures in the principle amount of $1,000,000 and warrants to acquire control or direction of up to 2,444,444 common shares (“Warrants”). Each Warrant entitles the holder to purchase one common share at an exercise price of $0.135 per common share for a period of three years. Before the issuance, StableView exercised control or direction over 28,605,584 Warrants representing approximately 19.69% of Clarocity’s outstanding common shares on a fully-converted basis. After the issuance, StableView exercised control or direction over 31,050,028 Warrants representing approximately 22.14% of Clarocity’s outstanding common shares on a fully-converted basis. This represents an increase of approximately 2.45% in the convertible securities over which StableView exercises control or direction.

The Warrants are held for investment purposes and StableView may, depending on market and other conditions, increase or decrease its control or direction over the Warrants or other securities of Clarocity whether through market transactions, private agreements, treasury issuances, exercise of convertible securities, or otherwise.

For more information, or to obtain a copy of the early warning report filed under National Instrument 62-103, please contact:

StableView Asset Management Inc.
Attention: Colin Fisher
Telephone: 416-920-8600

SOURCE: StableView Asset Management

ReleaseID: 458664

LOS ANGELES, CA / ACCESSWIRE / March 31, 2017 / Lundin Law PC, a shareholder rights firm, announces that it is investigating claims against U.S. Physical Therapy, Inc. (“U.S. Physical Therapy” or the “Company”) (NYSE: USPH) concerning possible violations of federal securities laws.

To get more information about this investigation, please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or by email at brian@lundinlawpc.com.

On March 16, 2017, U.S. Physical Therapy revealed it had found an accounting error stating “it was determined that the Company’s historical accounting for redeemable non-controlling interests of acquired partnerships was incorrect due to the fact that those partnership agreements contain a provision that makes the non-controlling interests mandatorily redeemable and, thus incorrectly classified.”

U.S. Physical Therapy further commented that “[m]anagement has concluded that this error will result in the reporting of a material weakness in internal controls over financial reporting as they relate to this issue and that, as a result, ineffective internal controls over financial reporting. The error will require the restatement of previously issued financial statements.” When this information was revealed to the public, the value of U.S. Physical stock fell, causing investors harm.

Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding the rights of shareholders.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 458663

NEW YORK, NY / ACCESSWIRE / March 31, 2017 / The following statement is being issued by Levi & Korsinsky, LLP:

To: All Persons or Entities who purchased TRC Companies, Inc. (NYSE: TRR) stock prior to March 31, 2017.

You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of TRC Companies to affiliates of New Mountain Partners IV, L.P., an investment fund managed by New Mountain Capital, LLC. Under the terms of the transaction, TRC Companies shareholders will receive $17.55 per share. To learn more about the action and your rights, go to: http://zlk.9nl.com/trc-companies-trr, or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

Levi & Korsinsky is a national firm with offices in New York, Connecticut, California, and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits and have recovered
hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
30 Broad Street – 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 458662

NEW YORK, NY / ACCESSWIRE / March 31, 2017 / Celldex Therapeutics’ stock might be plummeting but Wall Street still remains adamant that the company’s stock could rise significantly in value. The company’s kiln still has metal heating up, with clinical drug trials research still ongoing. Despite the huge expenses involved in the research, analysts insist that there is still time for the market to adjust and accommodate the potential of Celldex’s stock price. Everything remained quiet regarding PDL BioPharma, with the company having a rough time maintaining stability with the stock price, and meeting the average trade volume. Here’s a closer look at the company’s performance yesterday.

RDI Initiates
Coverage:

Celldex Therapeutics,
Inc. https://ub.rdinvesting.com/news/?ticker=CLDX

PDL BioPharma Inc. https://ub.rdinvesting.com/news/?ticker=PDLI

The therapeutic company’s shares dropped 2.96% yesterday to close at $3.60. The dip however, comes amid speculations from Wall Street that the company’s stock has the potential to double up by the end of the year. Companies involved in the speculation include Idera Pharmaceuticals, Opko Health and Celldex Therapeutics. Celldex is still recovering from the failed experimental procedures involving glioblastoma vaccine Rintega late last year.

The company is currently engaged in triple-negative Breast Cancer research, with Glembatumumab vedotin (glemba) slated to be the company’s first drug. There are still other clinical trials in the pipeline, with the probability of success deemed “very likely”. This is to say that once the trials are over, the company’s stock might be the biggest beneficiary.

Access RDI’s Celldex Therapeutics Research Report at: https://ub.rdinvesting.com/news/?ticker=CLDX

PDL BioPharma’s stock dipped 1.37% yesterday to close at $2.16. The company traded 2.4 million shares yesterday as compared to the 50 day average volume of 1.7mn shares. Pharmaceuticals remain NASDAQ’s riskiest sector, with the NASDAQ Composite Index more than doubling since 2011. Biotech companies rarely make money, and the ones that do more often than not have established brands that already enjoy commercial success. Clinical research and manufacturing costs tend to be higher than revenue, with investments helping to keep the companies afloat.

Access RDI’s PDL BioPharma Research Report at: https://ub.rdinvesting.com/news/?ticker=PDLI

Our Actionable Research on Celldex Therapeutics, Inc. (NASDAQ: CLDX) and PDL BioPharma Inc. (NASDAQ: PDLI) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 458640

NEW YORK, NY / ACCESSWIRE / March 31, 2017 / Levi & Korsinsky announces it has commenced an investigation of GWG Holdings, Inc. (NASDAQ: GWGH) concerning possible breaches of Delaware law by the board of directors of the company. To obtain additional information, go to: http://zlk.9nl.com/gwg-holdings-gwgh, or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Eduard Korsinsky, Esq.
30 Broad Street- 24th Floor
New York, NY10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 458661